+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID04676828

Phase II Trial of SPECT-Guided Functional Lung Avoidance Radiation Therapy for Patients With Lung Cancer Receiving Curative Chemo-Radiotherapy

Led by University of Aarhus · Updated on 2026-02-24

90

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new method called functional lung avoidance radiotherapy for patients with advanced lung cancer undergoing chemo-radiotherapy. This approach uses a special imaging scan called perfusion single photon emission SPECTCT to identify and protect highly functional areas of the lung from radiation. The study aims to see if this method improves lung toxicity outcomes compared to standard radiation therapy. Participants receive either SPECT-based radiation therapy that avoids highly functional lung areas or standard CT-based radiation therapy over 5 to 6.5 weeks. Both treatments are given with curative intent and may be combined with chemotherapy. The trial is randomized and includes a comparison between the new functional avoidance approach and the usual radiation treatment. During the study, participants will be monitored for lung toxicity from 1 to 12 months after treatment. Researchers will also assess quality of life, lung symptoms reported by patients, cancer progression, survival, and tumor control. Follow-up includes regular evaluations to track these outcomes and compare the effects of the two radiation approaches over one year.

CONDITIONS

Brief Title

Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer

Research Team

K

Katherina Farr, MD PhD FRACP

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here